Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9(®) to better battle prostate cancer progression.
about
Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis.Sorafenib with ASC-J9® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.Biological and pharmacological evaluation of dimethoxycurcumin: A metabolically stable curcumin analogue with a promising therapeutic potential.Total glucosides of paeony inhibits lipopolysaccharide-induced proliferation, migration and invasion in androgen insensitive prostate cancer cells.CCL5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment.Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.
P2860
Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9(®) to better battle prostate cancer progression.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Targeting inflammatory cytokin ...... e prostate cancer progression.
@en
type
label
Targeting inflammatory cytokin ...... e prostate cancer progression.
@en
prefLabel
Targeting inflammatory cytokin ...... e prostate cancer progression.
@en
P2860
P356
P1433
P1476
Targeting inflammatory cytokin ...... e prostate cancer progression.
@en
P2093
Chawnshang Chang
Kouji Izumi
P2860
P304
P356
10.4161/ONCI.26853
P577
2013-10-22T00:00:00Z